BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2022

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Three Month Period Ended:
	March 31,		March 31,
	2022		2021
Research and development services (over-time)	$	219,898	$	124,760
Clinical laboratory testing services (point-in-time)		4,331,867		1,425,980
Clinical laboratory testing services (over-time)		1,158,375		128,900
Product and authentication services (point-in-time):
Supply chain		115,463		67,057
Asset marking		141,657		140,169
Diagnostic test kits		180,023		784,676
Total	$	6,147,283	$	2,671,542

	Six Month Period Ended:
	March 31,		March 31,
	2022		2021
Research and development services (over-time)	$	325,591	$	388,473
Clinical laboratory testing services (point-in-time)		6,205,589		2,003,250
Clinical laboratory testing services (over-time)		2,484,775		324,400
Product and authentication services (point-in-time):
Supply chain		527,295		99,999
Asset marking		246,895		291,927
Diagnostic test kits		522,844		1,179,634
Total	$	10,312,989	$	4,287,683

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		March 31,		$
	Balance sheet classification	2021		2022		change
Contract liabilities	Deferred revenue	$	281,000	$	393,656	$	112,656

Schedule of anti-dilutive securities not included computation of net loss per share

	2022	2021
Warrants	2,239,963	776,518
Stock options	1,067,614	408,085
Total	3,307,577	1,184,603